Introduction

The Women’s Health Market Outlook to 2016 provides comprehensive coverage of the women’s health market, a incorporating disease overview and detailed epidemiological analyses of the major indications. This report makes an in-depth assessment of marketed products, R&D pipelines, market share data, sales forecast and the competitive landscape for the major players.

Features and benefits

* Understand how recent events are affecting the performance of major products, and how their marketers are confronting competitive market changes.
* Compare the franchises of the leading companies in global womens health market, and understand how the market share of these companies will change.
* Assess key pipeline products by indication, ongoing trials, recent product launches and key developments in R&D.
* Identify the challenges confronted by leading players, and learn from their business strategies.
* Forecast of the leading marketed and pipeline products through to 2015.

Highlights

The global women’s health market in 2010 was valued at $23.3bn, with a CAGR of 4.2% (2005–10). It is forecasted to reach $32.8bn by 2016 at a CAGR of 5.9% (2010–16).
Hormonal contraceptives was the largest selling drug class in 2010 and is projected to reach $15.2bn by 2016. This class is dominated by generics and branded generic products. Osteoporosis treatment is the second largest drug class and consists of many blockbuster brands like Fosamax, Actonel, Evista, Bonvivia.
The top 10 brands in the women’s health market accounted for 39.5% of total sales in 2010. Seven out of the top 10 brands are forecasted to decline during the forecast period due to impending or expired patents.

Your key questions answered

* What will be the major growth indications and the accompanying growth drivers in the women’s health market to 2016?
* Which were the leading players in the women’s health market in 2010? Which companies are best positioned to succeed to 2016?
* Which therapeutic categories and products are forecast to have the highest levels of commercial potential over the period 2010-16?
* What is a successful commercial and marketing strategy in the womens health market?
* What are the significant market and pipeline developments that may shape corporate strategies for leading drug majors in this market?

Executive Summary
Overview and epidemiology of women’s health
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Overview and epidemiology of women’s health
Summary
Introduction
Osteoporosis
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormonal contraception
Overview
Diagnosis treatment and management
Epidemiology
Forecast epidemiology
Hormone replacement therapies
Overview
Diagnosis, treatment and management
Infertility treatment
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Global market analysis
Summary
Market analysis by geography
Market analysis by therapy area
Hormonal contraceptives
Osteoporosis treatment
Hormone replacement therapy (HRT)
Infertility treatment
Key events in women’s health market
Merck Serono sells womens health division to Teva
Gedeon Richter extends womens health franchise with PregLem acquisition
Boehringer Ingelheim discontinued the development of its female desire drug, flibanserin
Eli Lillys arzoxifene misses secondary endpoint in critical osteoporosis trial
Bayer’s Yaz and Yasmin get US label update
Research deal between Bayer and Chinese hospital for womens health
Leading brand dynamics
Actonel (Risedronate) – Warner Chilcott, Sanofi
Evista (raloxifene) – Eli Lilly
Bonviva/Boniva (ibandronic acid) – Roche/GlaxoSmithKline
Premarin (conjugated estrogens) – Pfizer
Fosamax (alendronate) – Merck & Co
Yaz/Yasmin (drospirenone + ethinyl estradiol) – Bayer
Mirena (levonorgestrel) – Bayer
Gonal F (follitropin beta) – Merck KGaA
NuvaRing (ethinyl estradiol + etonogestrel) – Merck & Co.
Global women’s health sales forecast
Pipeline analysis
Summary
Introduction
Women’s health pipeline
Leading drugs in development
Profiles of key pipeline products
Prolia (denosumab) – Amgen
Viviant/Conbriza (bazedoxifene) – Pfizer
LCS (ultra low-dose levonorgestrel releasing IUD) – Bayer
Aprela (bazedoxifene and conjugated estrogen) – Pfizer
MK-0822 (odanacatib) – Merck
Elonva (corifollitropin alfa) – Merck
Nomac E2 (nomegestrol and estradiol) – Merck & Co.
WC3026/ Generess (norethindrone + ethinyl estradiol) – Warner Chilcott/Watson
Natazia/Qlaira (estradiol valerate and dienogest) – Bayer
SMC021 (synthetic oral salmon calcitonin) – Novartis
FC Patch Low (gestodene and ethinyl estradiol transdermal patch) – Bayer
DR2011 (progesterone vaginal ring) – Teva
EllaOne (ulipristal acetate) – HRA Pharma/Watson
Pipeline forecast of leading drugs in development
Competitive landscape
Summary
Introduction
Sales performance of leading players
Bayer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Merck & Co.
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Eli Lilly
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Warner Chilcott
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Pfizer
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Teva
Marketed product portfolio
Pipeline analysis
Strategic and growth analysis
Appendix
Scope
Key women’s health diseases covered in this report
Methodology
Epidemiology forecast
Market forecast
Epidemiology forecast
References
Journal articles
Conference proceedings
Important websites
Glossary/abbreviations